Details for Patent: 8,247,415
✉ Email this page to a colleague
Which drugs does patent 8,247,415 protect, and when does it expire?
Patent 8,247,415 protects GEMTESA and is included in one NDA.
This patent has fifty-nine patent family members in forty-four countries.
Summary for Patent: 8,247,415
| Title: | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
| Abstract: | The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. |
| Inventor(s): | Richard Berger, Lehua Chang, Scott D. Edmondson, Stephen D. Goble, Sookhee Nicole Ha, Nam Fung Kar, Ihor E. Kopka, Bing Li, Gregori J. Morriello, Chris R. Moyes, Dong-ming Shen, Liping Wang, Cheng Zhu |
| Assignee: | Merck Sharp and Dohme LLC |
| Application Number: | US12/417,239 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,247,415
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY IN ADULT MALES ON PHARMACOLOGICAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (BPH) | ⤷ Start Trial | ||
| Sumitomo Pharma Am | GEMTESA | vibegron | TABLET;ORAL | 213006-001 | Dec 23, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,247,415
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2276756 | ⤷ Start Trial | 301305 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2276756 | ⤷ Start Trial | CA 2024 00054 | Denmark | ⤷ Start Trial |
| European Patent Office | 2276756 | ⤷ Start Trial | LUC00366 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2276756 | ⤷ Start Trial | CR 2024 00054 | Denmark | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
